Gyre Therapeutics, Inc. Increase (Decrease) in Restricted Cash
Gyre Therapeutics, Inc. (GYRE) reported Increase (Decrease) in Restricted Cash of $57.00 thousand for the 12-month period ending 2017-12-31, per its 10-K filed 2018-03-19.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInRestrictedCash · last filed 2018-03-19
- Gyre Therapeutics, Inc. increase (decrease) in restricted cash for the quarter ending 2017-12-31 was $8.00K.
- Gyre Therapeutics, Inc. increase (decrease) in restricted cash for the quarter ending 2017-09-30 was $12.00K.
- Gyre Therapeutics, Inc. increase (decrease) in restricted cash for the quarter ending 2017-06-30 was $18.00K.
- Gyre Therapeutics, Inc. increase (decrease) in restricted cash for the quarter ending 2017-03-31 was $19.00K, a 1800.00% increase year-over-year.
- Gyre Therapeutics, Inc. increase (decrease) in restricted cash for fiscal 2017 was $57.00K, a 1040.00% increase from fiscal 2016.
- Gyre Therapeutics, Inc. increase (decrease) in restricted cash for fiscal 2016 was $5.00K, a 96.00% decline from fiscal 2015.
- Gyre Therapeutics, Inc. increase (decrease) in restricted cash for fiscal 2015 was $125.00K.
| Period end | Increase (Decrease) in Restricted Cash 3 month | Increase (Decrease) in Restricted Cash 6 month | Increase (Decrease) in Restricted Cash 9 month | Increase (Decrease) in Restricted Cash 12 month |
|---|---|---|---|---|
| 2017-12-31 | $8.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-19 | $20.00K derived: sum of 2 quarters · filed 2018-03-19 | $38.00K derived: sum of 3 quarters · filed 2018-03-19 | $57.00K 10-K · filed 2018-03-19 |
| 2017-09-30 | $12.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-02 | $30.00K derived: sum of 2 quarters · filed 2017-11-02 | $49.00K 10-Q · filed 2017-11-02 | |
| 2017-06-30 | $18.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | $37.00K 10-Q · filed 2017-08-03 | ||
| 2017-03-31 | $19.00K 10-Q · filed 2017-05-11 | |||
| 2016-12-31 | $5.00K 10-K · filed 2018-03-19 | |||
| 2016-03-31 | $1.00K 10-Q · filed 2017-05-11 | $1.00K derived: sum of 2 quarters · filed 2017-05-11 | $69.00K derived: sum of 3 quarters · filed 2017-05-11 | $69.00K derived: sum of 4 quarters · filed 2017-05-11 |
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-08 | $68.00K derived: sum of 2 quarters · filed 2017-03-08 | $68.00K derived: sum of 3 quarters · filed 2017-03-08 | $125.00K 10-K · filed 2017-03-08 |
| 2015-09-30 | $68.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | $68.00K derived: sum of 2 quarters · filed 2016-11-03 | $125.00K 10-Q · filed 2016-11-03 | |
| 2015-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | $57.00K 10-Q · filed 2016-08-04 | ||
| 2015-03-31 | $57.00K 10-Q · filed 2016-05-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |